Insurance Delays Add Costs to CAR T-Cell Therapy: Ravi Vij, MD, MBA
Written by
American Journal Managed Care
Published
0
comments
0
min
Ravi Vij, MD, MBA, explains how insurance-related delays in CAR T approval slow treatment initiation, increase interim therapy costs, and contribute to patient burden.